TGFB1 and lymphedema: These findings provide a cellular mechanism for our observation which is the number of CD26+ cells is increased significantly in lymphedematous tissues of patients with BCRL and that treatment with TGF‐β1 neutralising antibodies decreases the number of these cells in the mouse tail model of lymphedema.